South Africa, Colombia and others are fighting drugmakers over access to TB and HIV drugs

South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV. In the COVID-19 pandemic, rich countries bought most of the world’s vaccines early, leaving few shots for poor countries and creating a disparity the World Health Organization called “a catastrophic moral failure.” Now, poorer countries are trying to become more self-reliant “because they’ve realized after COVID they can’t count on anyone else,” said Brook Baker, who studies treatment-access issues at Northeastern University.

Related Keywords

South Africa ,Kwazulu ,Eastern Cape ,Colombia ,Belarus ,London ,City Of ,United Kingdom ,Brazil ,Washington ,United States ,Ukraine ,Colombian ,Brazilian ,South African ,Natal ,Christophe Perrin ,Nelson Mandela ,Petro Terblanche ,Zolelwa Sifumba ,Peter Maybarduk ,Andy Gray ,Afrigen Biologics ,Lynette Keneilwe Mabote ,World Health Organization ,Pfizer ,African Department ,Johnson ,Northeastern University ,Doctors Without Borders ,Treatment Action Group ,University Of Kwazulu ,Brook Baker ,President Nelson Mandela ,Without Borders ,Lynette Keneilwe Mabote Eyde ,Treatment Action ,Pharmaceutical Companies ,South African Government ,Poor Countries ,Frica ,Covid ,